Asian Journal of Research and Reports in Endocrinology

Diabetic cardiomyopathy (DCM) is a distinct cardiac disorder in individuals with diabetes, characterized by structural and functional myocardial abnormalities that occur independently of coronary artery disease, hypertension, or valvular heart disease. Epidemiological studies report a prevalence of up to 22% among patients with diabetes, with a rising incidence over time that is further amplified by poor glycemic control. The pathogenesis of DCM is multifactorial, involving chronic hyperglycemia, insulin resistance, inflammation, oxidative stress, disordered calcium handling, and dysregulation of the renin-angiotensin-aldosterone system. These processes contribute to myocardial fibrosis, hypertrophy, apoptosis, and progressive ventricular dysfunction. Altered cardiac metabolism, marked by increased fatty acid utilization and reduced glucose oxidation, further promotes lipotoxicity, mitochondrial dysfunction, and impaired myocardial contractility.

Diabetic cardiomyopathy progresses from risk factors to overt heart failure. Stage A includes all diabetic patients at high risk, Stage B shows asymptomatic structural or functional abnormalities, and Stages C-D involve symptomatic heart failure. Early detection relies on echocardiography and cardiac biomarkers.

Management of DCM requires a comprehensive approach, including lifestyle modification, optimal glycemic and lipid control, and cardiovascular therapies. Pharmacologic agents such as metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and statins provide cardioprotective benefits by improving myocardial metabolism, reducing fibrosis, and enhancing cardiac function. Emerging therapies targeting metabolic, inflammatory, and fibrotic pathways offer potential for early intervention. Early recognition and individualized treatment strategies are essential to reduce morbidity, prevent progression to heart failure, and improve outcomes in patients with diabetes.